On Tuesday, Roen Surgical, a surgical robot platform company, announced its plans to export Zamenix, their artificial intelligence (AI) powered kidney stone surgery robot, to Indonesia.
Mandaya Royal Hospital, a premium healthcare facility in Jakarta, Indonesia, will be the first to implement Zamenix. The hospital aims to significantly improve the accuracy, safety, and efficiency of kidney stone surgeries with this cutting-edge technology.
Roen Surgical’s decision to target Indonesia as its initial Southeast Asian market entry point was strategic. The country’s massive population of approximately 286 million, coupled with a robust economic growth rate of around 5% and a relatively streamlined medical device approval process, presents an attractive market opportunity.
In preparation for this export, Roen Surgical has been actively raising awareness about Zamenix in Indonesia. The company participated in major urology conferences, including the Indonesian Urology Education Conference (MCUE) and the Asian Urological Association (UAA). They also collaborated closely with local medical professionals and conducted comprehensive user training sessions.
To date, local medical teams have performed 23 demo clinical trials. These trials have yielded impressive results, with physicians reporting high satisfaction rates in surgical accuracy, ease of operation, and patient safety. Notably, no significant complications have been reported.
Marking a new chapter in their partnership, Roen Surgical and Mandaya Royal Hospital have signed a strategic memorandum of understanding (MOU). This agreement outlines plans for collaboration in clinical research, education, and marketing. Both parties have committed to establishing a long-term cooperation framework, encompassing joint clinical research and comprehensive training programs for medical staff.
As part of this agreement, Mandaya Hospital will become the official training center for Zamenix. The hospital will offer systematic training programs and provide real-time technical support to local medical professionals, ensuring optimal use of the technology.
Building on this initial foray into Indonesia, Roen Surgical plans to expand its clinical presence through partnerships with reference hospitals and key opinion leaders (KOLs) in the country. The company is also eyeing expansion into neighboring markets, such as Thailand. Looking ahead, Roen Surgical aims to accelerate its global market entry, following roadmaps for the Food and Drug Administration (FDA) approval in the U.S. and European certification.
A spokesperson for Mandaya Hospital praised Zamenix, stating that this exceptional surgical robot significantly enhances the precision of complex kidney stone removal procedures while prioritizing patient safety and improving convenience for medical staff. It believes that introducing Zamenix will set a new benchmark for technology-driven urological care in Indonesia.
Kwon Dong-soo, Chief Executive Officer (CEO) of Roen Surgical, expressed his enthusiasm: Its first export comes after extensive local demo surgeries that confirmed Zamenix’s safety and efficacy. The mission with Zamenix is to provide patients with safe, effective treatments while ensuring unparalleled accuracy for medical professionals. In the coming year, it is committed to ramping up the export efforts across Southeast Asia.
Concurrently, Zamenix is undergoing clinical trials in South Korea, involving 232 patients across several prestigious medical institutions, including Samsung Medical Center, Yeungnam University Medical Center, Kyungpook National University Hospital, Yangsan Busan National University Hospital, and Korea University Anam Hospital’s urology departments. Approximately 90% of these trials have been completed, with no significant adverse effects reported thus far.